A trial of recombinant human interleukin-1 in patients with severe refractory aplastic anaemia.
We report here the effects of in vivo administration of recombinant interleukin-1 alpha (rIL-1 alpha) to patients with severe, idiopathic aplastic anaemia. Four patients who were refractory to immunosuppressive therapy and were not bone marrow transplantation candidates received daily doses of 0.03 microgram/kg and 0.10 microgram/kg intravenously as 5 d courses. No significant changes in either peripheral blood counts or bone marrow cellularity were observed at either dose during or following therapy. Two patients showed increased numbers of bone marrow progenitor colonies. Lymphocyte phenotyping demonstrated an elevated percentage of CD8+/DR+ activated suppressor T lymphocytes prior to therapy. After rIL-1 alpha administration, the percentage of CD8+/DR+ cells was reduced or returned to normal in all patients. Significant side-effects included fever, rigours, fatigue, headache and nausea. Transient hypotension was observed at both doses in all patients. These results suggest that while rIL-1 alpha can be safely administered, no significant haematologic improvement was observed in patients with severe aplastic anaemia.
Walsh
C E
CE
Clinical Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, Md. 20892.
Liu
J M
JM
Anderson
S M
SM
Rossio
J L
JL
Nienhuis
A W
AW
Young
N S
NS
D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000753:Anemia, Refractory / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007375:Interleukin-1 / Q000627:therapeutic use*; D016131:Lymphocyte Subsets / Q000473:pathology; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*
D007375:Interleukin-1; D011994:Recombinant Proteins